Fred R Hirsch Selected Research

B7-H1 Antigen

1/2022	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
1/2021	Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
1/2021	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC.
1/2021	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
1/2020	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
1/2020	Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer.
1/2020	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.
1/2019	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
10/2018	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
3/2017	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fred R Hirsch Research Topics

Disease

131	Neoplasms (Cancer) 08/2022 - 05/2002
124	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022 - 02/2002
118	Lung Neoplasms (Lung Cancer) 01/2022 - 02/2002
19	Adenocarcinoma 05/2022 - 02/2002
17	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 06/2022 - 05/2002
13	Adenocarcinoma of Lung 01/2021 - 02/2011
12	Disease Progression 09/2021 - 09/2011
11	Neoplasm Metastasis (Metastasis) 06/2021 - 05/2002
8	Carcinoma (Carcinomatosis) 01/2021 - 07/2002
8	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 02/2002
8	Squamous Cell Carcinoma of Head and Neck 01/2017 - 09/2006
8	Carcinogenesis 12/2013 - 03/2002
6	Mesothelioma 01/2022 - 01/2017
5	Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar) 01/2018 - 10/2003
5	Colorectal Neoplasms (Colorectal Cancer) 04/2013 - 03/2009
4	Malignant Mesothelioma 01/2020 - 09/2012
4	Exanthema (Rash) 01/2018 - 03/2015
4	Hemorrhage 01/2017 - 04/2009
4	Breast Neoplasms (Breast Cancer) 02/2004 - 02/2002
3	COVID-19 08/2022 - 01/2022
3	Anemia 04/2021 - 08/2003
3	Lymphatic Metastasis 12/2019 - 01/2013
3	Chronic Obstructive Pulmonary Disease (COPD) 11/2007 - 01/2004
2	Pneumonia (Pneumonitis) 01/2022 - 01/2017
2	Acne Vulgaris 01/2018 - 07/2015
2	Lymphoma (Lymphomas) 01/2018 - 01/2017
2	Ovarian Neoplasms (Ovarian Cancer) 06/2016 - 12/2015
2	Brain Neoplasms (Brain Tumor) 01/2016 - 12/2013
2	Squamous Cell Neoplasms (Squamous Cell Cancer) 10/2015 - 08/2013

Drug/Important Bio-Agent (IBA)

67	ErbB Receptors (EGF Receptor)IBA 06/2019 - 02/2002
53	Biomarkers (Surrogate Marker)IBA 06/2022 - 07/2002
42	Proteins (Proteins, Gene)FDA Link 05/2022 - 02/2002
40	Tyrosine Kinase InhibitorsIBA 01/2022 - 08/2005
22	Gefitinib (Iressa)FDA Link 10/2018 - 05/2005
17	Cetuximab (Erbitux)FDA Link 01/2022 - 04/2008
17	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 12/2006
16	B7-H1 AntigenIBA 01/2022 - 07/2015
15	Pharmaceutical PreparationsIBA 12/2018 - 08/2003
14	Monoclonal AntibodiesIBA 02/2021 - 02/2002
11	PlatinumIBA 09/2021 - 09/2006
11	Messenger RNA (mRNA)IBA 11/2020 - 05/2006
11	Biological ProductsIBA 10/2018 - 08/2003
10	Immune Checkpoint InhibitorsIBA 11/2022 - 01/2018
9	Pemetrexed (MTA)FDA Link 01/2016 - 02/2011
8	RNA (Ribonucleic Acid)IBA 05/2022 - 07/2002
8	AntibodiesIBA 06/2021 - 03/2008
8	LigandsIBA 01/2021 - 05/2005
8	CrizotinibIBA 04/2016 - 09/2012
7	Anaplastic Lymphoma KinaseIBA 01/2019 - 01/2011
7	Paclitaxel (Taxol)FDA LinkGeneric 03/2016 - 08/2008
6	MucinsIBA 02/2021 - 02/2011
6	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2020 - 12/2006
6	Carboplatin (JM8)FDA LinkGeneric 03/2016 - 08/2008
6	DNA (Deoxyribonucleic Acid)IBA 08/2011 - 12/2002
5	MicroRNAs (MicroRNA)IBA 08/2018 - 02/2013
5	Bevacizumab (Avastin)FDA Link 01/2018 - 02/2011
5	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 03/2015
5	Trastuzumab (Herceptin)FDA Link 02/2004 - 02/2002
4	Immunoglobulins (Immunoglobulin)IBA 02/2021 - 01/2018
4	Phosphotransferases (Kinase)IBA 01/2020 - 01/2017
4	SilverIBA 01/2019 - 02/2012
4	Cell-Free Nucleic AcidsIBA 03/2018 - 01/2017
4	necitumumabIBA 01/2018 - 03/2015
4	Gemcitabine FDA Link 01/2016 - 05/2002
4	CarcinogensIBA 09/2009 - 03/2002
3	AfatinibIBA 01/2022 - 01/2014
3	NivolumabIBA 09/2021 - 01/2018
3	IpilimumabIBA 09/2021 - 01/2018
3	ponatinibIBA 01/2019 - 06/2014
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2017 - 09/2008
3	ORALIT (ORS)IBA 01/2017 - 06/2004
3	Cadherins (E-Cadherin)IBA 01/2017 - 05/2002
3	GoldIBA 08/2013 - 11/2009
3	Volatile Organic CompoundsIBA 08/2013 - 11/2009
3	Insulin (Novolin)FDA Link 07/2013 - 05/2010
3	Thymidylate SynthaseIBA 01/2013 - 04/2012
3	Insulin-Like PeptidesIBA 12/2010 - 08/2008
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2010 - 05/2005
3	Indicators and Reagents (Reagents)IBA 04/2010 - 08/2005
3	SmokeIBA 09/2009 - 03/2002
2	VaccinesIBA 01/2022 - 01/2009
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 06/2013
2	Docetaxel (Taxotere)FDA Link 01/2022 - 11/2013
2	atezolizumabIBA 01/2022 - 10/2018
2	Hemoglobins (Hemoglobin)IBA 04/2021 - 09/2006
2	Formaldehyde (Formol)FDA Link 10/2020 - 02/2013
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 01/2018
2	Angiogenesis InhibitorsIBA 01/2019 - 01/2018
2	onartuzumabIBA 01/2017 - 09/2014
2	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 07/2015 - 06/2009

Therapy/Procedure

84	Therapeutics 11/2022 - 05/2002
34	Drug Therapy (Chemotherapy) 01/2022 - 08/2003
26	Immunotherapy 01/2022 - 01/2016
12	Chemoprevention 02/2013 - 02/2002
7	Radiotherapy 01/2021 - 08/2003
5	Precision Medicine 01/2018 - 10/2010
2	Neoadjuvant Therapy 01/2020 - 12/2018
2	Pneumonectomy (Lung Volume Reduction) 01/2020 - 12/2002
2	Aftercare (After-Treatment) 01/2017 - 06/2007
2	Molecular Targeted Therapy 01/2017 - 08/2003